Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 1,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disorder Clear all
Completed No phase listed Observational Accepts healthy volunteers

Accuracy of the Red Reflex Test in the Pediatric Population

NCT04125043
View directory record Official record
Conditions
Abnormal Vitreous Humor Morphology, Abnormal Choroid Morphology, Optic Nerve Diseases, Retinal Disease, Retinal Hemorrhage
Interventions
Direct ophthalmoscope
Diagnostic Test
Lead sponsor
Children's National Research Institute
Other
Eligibility
Up to 18 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Not applicable Interventional

Confronting Unequal Eye Care in Pennsylvania

NCT01179555
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetes Mellitus, Type 2, Glaucoma
Interventions
Behavioral Activation, Supportive Therapy
Behavioral
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 31, 2026, 6:40 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

NCT04002310
View directory record Official record
Conditions
Macular Degeneration
Interventions
BI 754132
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Beverly Hills, California • Pensacola, Florida • Winter Haven, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

NCT00407355
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
Drug
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 31, 2026, 6:40 AM EDT
Terminated No phase listed Observational

Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy

NCT00346372
View directory record Official record
Conditions
Ocular Melanoma
Interventions
Not listed
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 31, 2026, 6:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Intraoperative OCT Guidance of Intraocular Surgery II

NCT03713268
View directory record Official record
Conditions
Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions
Microscope integrated optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
4 Weeks and older
Enrollment
262 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

Aflibercept Injection for Proliferative Diabetic Retinopathy

NCT01805297
View directory record Official record
Conditions
Vitreous Hemorrhage
Interventions
Intravitreal Aflibercept Injection, Standard Vitrectomy
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1 Interventional

Vitamin E to Treat Uveitis-Associated Macular Edema

NCT00021645
View directory record Official record
Conditions
Cystoid Macular Edema, Uveitis
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 6:40 AM EDT
Not listed Not applicable Interventional

Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion

NCT01581151
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Dexamethasone intravitreal implant, Monthly Ranibizumab
Drug
Lead sponsor
Brian Burke, MPH
Other
Eligibility
18 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

NCT01414153
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea, sham injection
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
44
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Not applicable Interventional Results available

Argus® II Retinal Stimulation System Feasibility Protocol

NCT00407602
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Implant of Argus II Retinal Prosthesis
Device
Lead sponsor
Second Sight Medical Products
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 31, 2026, 6:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Visual Remapping to Aid Reading With Field Loss

NCT03848663
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Traditional Remapping, Personalized Remapping
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 31, 2026, 6:40 AM EDT
Terminated Phase 2 Interventional

Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy

NCT01675947
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Sirolimus, Lidocaine
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
55 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
13
States / cities
Loma Linda, California • Sacramento, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

NCT03981549
View directory record Official record
Conditions
Central Retinal Vein Occlusion
Interventions
Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy
Biological
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 31, 2026, 6:40 AM EDT
Withdrawn Phase 2 Interventional

Intra-arterial Chemotherapy for Advanced Intraocular Retinoblastoma

NCT01151748
View directory record Official record
Conditions
Retinoblastoma, Eye Cancer
Interventions
Intra-arterial infusion of chemotherapy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 31, 2026, 6:40 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

NCT03999801
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
AbbVie
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 31, 2026, 6:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Triton Agreement and Precision Study

NCT03080714
View directory record Official record
Conditions
Healthy Eyes, Eye Diseases
Interventions
Topcon DRI OCT Triton (plus), 3D OCT-1 Maestro
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Willmar, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 31, 2026, 6:40 AM EDT
Recruiting Phase 2 Interventional

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema

NCT07812090
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Oral BGE-102, Oral Placebo Matching BGE-102, Anti-VEGF, Sham
Drug · Other
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Bakersfield, California • Glendale, California • Mountain View, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 31, 2026, 6:40 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT01577381
View directory record Official record
Conditions
Age-Related Maculopathy
Interventions
RN6G, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
83
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 1 Interventional

Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5

NCT00722384
View directory record Official record
Conditions
Macular Degeneration
Interventions
bevasiranib
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2008 · Synced Oct 31, 2026, 6:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

NCT01225146
View directory record Official record
Conditions
Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
Interventions
ranibizumab
Drug
Lead sponsor
David M. Brown, M.D.
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial

NCT02374060
View directory record Official record
Conditions
Macular Edema, Uveitis
Interventions
Periocular triamcinolone 40 mg, Intravitreal triamcinolone 4 mg, Dexamethasone intravitreal implant
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
23
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 31, 2026, 6:40 AM EDT
Completed Phase 2 Interventional Results available

OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration

NCT00306488
View directory record Official record
Conditions
Geographic Atrophy, Age-Related Macular Degeneration, AMD
Interventions
OT-551 antioxidant eye drop
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
60 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 31, 2026, 6:40 AM EDT
Completed No phase listed Observational

Seven Year Update of Macular Degeneration Patients

NCT01256827
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
12
States / cities
Beverly Hills, California • Los Angeles, California • Mountain View, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 31, 2026, 6:40 AM EDT